EUVIMEDEUVIMED entdecken
Crossref

Abstract 1096: Sirolimus Delivery from Surmodics’ Sundance drug coated balloon (DCB)

s. hossainy, J. Slager, T. Kloke, A. Finn

Stroke: Vascular and Interventional Neurology · 18.10.2026 · 6 (Suppl_1)

DOI: 10.1161/svi270000_1096 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Stroke: Vascular and Interventional Neurology, erschienen am 18.10.2026. Verfasst von s. hossainy und 3 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Sirolimus Delivery from Surmodics’ Sundance drug coated balloon (DCB) .

Introduction

In patients with occlusive cardiovascular disease resulting from atherosclerotic lesion, clinical data suggest that paclitaxel eluting local therapies from drug eluting stent (DES) or drug-coated balloon (DCB) may have limitations compared to multi-modal sirolimus-based local treatments. The Sirolimus sustained-release DCB is potentially applicable in difficult lesions including Intra Cranial Artery Disease (ICAD).

Methods

Surmodics has engineered a novel microcrystalline sirolimus-loaded Sundance DCB with a unique local pharmacokinetic (PK) feature. Sundance performance was evaluated in large number of animal studies and in SWING below the knee clinical trial. Drug morphology, coating physicochemical properties, and multiple-dose local PK were quantified by analytical characterization. Pharmacokinetic (PK) data was further analyzed by quantitative mass transport mathematical modeling.

Results

Preclinical studies revealed a highly differentiated Sirolimus PK profile relative to existing technologies. (Figure 1A). Quantitative mass transport analysis indicated a sustained intramural drug distribution driven by a unique long-lasting, constant boundary condition. Preclinical studies also demonstrate quantifiable biological effects in treated vessels. The SWING clinical trial enrolled 35 patients with infrapopliteal disease in a challenging CLTI population. The Sundance DCB demonstrated an excellent safety profile and an estimated 24-month primary patency over 84% (per protocol). Significant clinical improvement and durable patient benefit was observed through 24 months. The distinctive PK profile is consistent with, and may underlie, the differentiated clinical outcomes.

Conclusion

These findings highlight the Sundance DCB technology as a unique next-generation platform for controlled vascular drug delivery including ICAD, enabled by proprietary microcrystalline sirolimus formulation and optimized surface engineering. Figure 1. (A) Pharmacokinetic profile of the Sundance DCB, as compared to competitor reported studies. Sundance DCB demonstrates arterial sirolimus concentrations above the therapeutic limit through 90 days. (B) Change in patient Rutherford clinical classification (RCC) in the SWING clinical trial through 24 months (per protocol). Improvement in RCC increased between the 1, 6, 12, and 24-month endpoints.

Zitieren

APA

hossainy, S., Slager, J., Kloke, T., & Finn, A. (2026). Abstract 1096: Sirolimus Delivery from Surmodics’ Sundance drug coated balloon (DCB). Stroke: Vascular and Interventional Neurology, 6(Suppl_1). https://doi.org/10.1161/svi270000_1096

Vancouver

hossainy S, Slager J, Kloke T, Finn A. Abstract 1096: Sirolimus Delivery from Surmodics’ Sundance drug coated balloon (DCB). Stroke: Vascular and Interventional Neurology. 2026;6(Suppl_1). doi:10.1161/svi270000_1096

BibTeX
@article{hossainy2026,
  author = {hossainy, s. and Slager, J. and Kloke, T. and Finn, A.},
  title = {Abstract 1096: Sirolimus Delivery from Surmodics’ Sundance drug coated balloon (DCB)},
  journal = {Stroke: Vascular and Interventional Neurology},
  year = {2026},
  volume = {6},
  number = {Suppl_1},
  doi = {10.1161/svi270000_1096}
}
Kostenlos starten →